

Oklahoma Health Care Authority

Drug Utilization Review Board

(DUR Board)

Meeting – December 10, 2025 @ 4:00pm

at the

Oklahoma Health Care Authority (OHCA)

4345 N. Lincoln Blvd.

Oklahoma City, Oklahoma 73105

NOTE: ***The DUR Board will meet at 4:00pm at OHCA (see address above). There will be Zoom access to this meeting; however, Zoom access will be set up in view-only mode with no voting, speaking, video, or chat box privileges. Zoom access will allow for viewing of the presentation slides as well as audio of the presentations and discussion during the meeting; however, the DUR Board meeting will not be delayed or rescheduled due to any technical issues that may arise.***

AGENDA

Discussion and action on the following items:

Items to be presented by Dr. Haymore, Chairman:

1. Call to Order

A. Roll Call – Dr. Wilcox

DUR Board Members:

Dr. Cassidy Blaiss –	participating in person
Dr. Christen Ground –	participating in person
Dr. Bret Haymore –	participating in person
Dr. Bethany Holderread –	participating in person
Dr. Matt John –	participating in person
Dr. Craig Kupiec –	participating in person
Dr. Lee Muñoz –	participating in person
Dr. Edna Patatanian –	participating in person
Dr. Jennifer Weakley –	participating in person

Viewing Access Only via Zoom:

Please register for the meeting at:

https://oklahoma.zoom.us/webinar/register/WN_B7-m8jKcQWaA9HEiV7QRQA

After registering, you will receive a confirmation email containing information about joining the webinar.

Or join by phone:

Dial: +1-602-753-0140 or +1-669-219-2599

Webinar ID: 928 6649 0447

Passcode: 80744869

Public Comment for Meeting:

- Speakers who wish to sign up for public comment at the OHCA DUR Board meeting may do so in writing by visiting the DUR Board page on the OHCA website at www.oklahoma.gov/ohca/about/boards-and-committees/drug-utilization-review/dur-board and completing the [Speaker Registration Form](#). Completed Speaker Registration forms should be submitted to DURPublicComment@okhca.org. Forms must be received after the DUR Board agenda has been posted and no later than 24 hours before the meeting.
- The DUR Board meeting will allow public comment and time will be limited to 40 minutes total for all speakers during the meeting. Each speaker will be given 5 minutes to speak at the public hearing. If more than 8 speakers properly request to speak, time will be divided evenly.
- Only 1 speaker per manufacturer will be allowed.
- Any speakers who sign up for public comment must attend the DUR Board meeting in person at OHCA (see above address). Public comment through Zoom will not be allowed for the DUR Board meeting.

Items to be presented by Dr. Haymore, Chairman:

2. Public Comment Forum

- A. Acknowledgement of Speakers for Public Comment

Items to be presented by Dr. Haymore, Chairman:

3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A

- A. November 12, 2025 DUR Board Meeting Minutes
- B. November 12, 2025 DUR Board Recommendations Memorandum

Non-presentation items reviewed by Dr. Moss, Dr. Haymore, Chairman:

4. Update on Medication Coverage Authorization Unit – See Appendix B

- A. Pharmacy Help Desk Activity for November 2025
- B. Medication Coverage Activity for November 2025

Items to be presented by Dr. Snyder, Dr. Haymore, Chairman:

5. Academic Detailing Program Update – See Appendix C

- A. Background
- B. Current Topics: Co-Prescribing Opioid Medications with Benzodiazepines (BZD) and Naloxone
- C. Prescriber Mailings and Results: Co-Prescribing Opioid Medications with BZD and Naloxone
- D. Summary

Items to be presented by Dr. Moss, Dr. Haymore, Chairman:

6. Action Item – SoonerCare Maintenance Drug List – See Appendix D

- 1. Introduction
- 2. SoonerCare Maintenance Drug List

3. College of Pharmacy Recommendations

Items to be presented by Dr. O'Halloran, Dr. Haymore, Chairman:

7. Action Item – Vote to Prior Authorize Brinsupri™ (Brensocatib) – See Appendix E

- A. Market News and Updates
- B. Brinsupri™ (Brensocatib) Product Summary
- C. College of Pharmacy Recommendations

Items to be presented by Dr. DeRemer, Dr. Haymore, Chairman:

8. Action Item – Vote to Prior Authorize Bildyos® (Denosumab-nxxp), Bilprevda® (Denosumab-nxxp), Bomynta® (Denosumab-bnht), Conexence® (Denosumab-bnht), Osenvelt® (Denosumab-bmwo), and Stoboclo® (Denosumab-bmwo) and Update the Approval Criteria for the Bone Density Regulators – See Appendix F

- A. Market News and Updates
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Wilson, Dr. Haymore, Chairman:

9. Action Item – Vote to Prior Authorize Forzinity™ (Elamipretide) – See Appendix G

- A. Market News and Updates
- B. Forzinity™ (Elamipretide) Product Summary
- C. College of Pharmacy Recommendations

Items to be presented by Dr. O'Halloran, Dr. Haymore, Chairman:

10. Action Item – Vote to Prior Authorize Rhapsido® (Remibrutinib) – See Appendix H

- A. Market News and Updates
- B. Rhapsido® (Remibrutinib) Product Summary
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Moss, Dr. Haymore, Chairman:

11. Action Item – Vote to Prior Authorize Harliku™ (Nitisinone), Orfadin® (Nitisinone), Nityr® (Nitisinone), and Sephience™ (Sepiapterin) and Update the Approval Criteria for the Amino Acid Disorder Medications – See Appendix I

- A. Market News and Updates
- B. Product Summaries
- C. Cost Comparisons
- D. College of Pharmacy Recommendations

Items to be presented by Dr. Wilson, Dr. Haymore, Chairman:

12. Action Item – Vote to Prior Authorize Anzupgo® (Delgocitinib 2% Cream) and Update the Approval Criteria for the Atopic Dermatitis (AD) Medications – See Appendix J

- A. Market News and Updates
- B. Anzupgo® (Delgocitinib 2% Cream) Product Summary
- C. Cost Comparisons
- D. College of Pharmacy Recommendations

Items to be presented by Dr. O'Halloran, Dr. Haymore, Chairman:

13. Action Item – Vote to Prior Authorize Omlyclo® (Omalizumab-igec) and Update the Approval Criteria for the Asthma and Chronic Obstructive Pulmonary Disease (COPD) Maintenance Medications – See Appendix K

- A. Market News and Updates
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Sinko, Dr. Haymore, Chairman:

14. Action Item – Vote to Prior Authorize Boruzu® (Bortezomib) and Lynozyfic™ (Linvoseltamab-gcpt) and Update the Approval Criteria for the Multiple Myeloma Medications – See Appendix L

- A. Market News and Updates
- B. Lynozyfic™ (Linvoseltamab-gcpt) Product Summary
- C. Cost Comparison: Bortezomib Products
- D. College of Pharmacy Recommendations

Items to be presented by Dr. Moss, Dr. Haymore, Chairman:

15. Action Item – Annual Review of Skysona® (Elivaldogene Autotemcel) – See Appendix M

- A. Current Prior Authorization Criteria
- B. Utilization of Skysona® (Elivaldogene Autotemcel)
- C. Prior Authorization of Skysona® (Elivaldogene Autotemcel)
- D. Market New and Updates
- E. College of Pharmacy Recommendations

Items to be presented by Dr. Sinko, Dr. Haymore, Chairman:

16. Annual Review of Skin Cancer Medications and 30-Day Notice to Prior Authorize Keytruda Qlex™ (Pembrolizumab/Berahyaluronidase alfa-pmph) and Opdivo Qvantig™ (Nivolumab/Hyaluronidase-nvhy) – See Appendix N

- A. Current Prior Authorization Criteria
- B. Utilization of Skin Cancer Medications
- C. Prior Authorization of Skin Cancer Medications
- D. Market News and Updates
- E. Product Summaries
- F. College of Pharmacy Recommendations
- G. Utilization Details of Skin Cancer Medications

Items to be presented by Dr. Moss, Dr. Haymore, Chairman:

17. Annual Review of Complement Inhibitors and Miscellaneous Immunomodulatory Agents and 30-Day Notice to Prior Authorize Imaavy™ (Nipocalimab-aahu) – See Appendix O

- A. Current Prior Authorization Criteria
- B. Utilization of Complement Inhibitors and Miscellaneous Immunomodulatory Agents
- C. Prior Authorization of Complement Inhibitors and Miscellaneous Immunomodulatory Agents
- D. Market News and Updates
- E. Imaavy™ (Nipocalimab-aahu) Product Summary
- F. Cost Comparisons
- G. College of Pharmacy Recommendations
- H. Utilization Details of Complement Inhibitors and Miscellaneous Immunomodulatory Agents

Items to be presented by Dr. DeRemer, Dr. Haymore, Chairman:

18. 30-Day Notice to Prior Authorize Aylglo™ [Immune Globulin (IG) Intravenous (IV), Human-stwk], Asceniv™ (IGIV, Human-slra), Cuvitru® (IG Subcutaneous (SC), Human), Gammagard Liquid® (IG Infusion, Human), Gammagard S/D® (IGIV, Human), Gammaplex® (IGIV, Human), Hizentra® (IGSC, Human), Panzyga® (IGIV, Human-ifas), Privigen® (IGIV, Human), and Xembify® (IGSC, Human-klhw) – See Appendix P

- A. Introduction
- B. Cost Comparisons
- C. College of Pharmacy Recommendations

Items to be presented by Dr. O'Halloran, Dr. Haymore, Chairman:

19. Annual Review of Thrombocytopenia Medications and 30-Day Notice to Prior Authorize Doptelet® Sprinkle (Avatrombopag) and Wayrilz™ (Rilzabrutinib) – See Appendix Q

- A. Current Prior Authorization Criteria
- B. Utilization of Thrombocytopenia Medications
- C. Prior Authorization of Thrombocytopenia Medications
- D. Market News and Updates
- E. Walyrilz™ (Rilzabrutinib) Product Summary
- F. College of Pharmacy Recommendations
- G. Utilization Details of Thrombocytopenia Medications

Items to be presented by Dr. Wilson, Dr. Haymore, Chairman:

20. Annual Review of Muscle Relaxant Medications and 30-Day Notice to Prior Authorize Atmeksi® (Methocarbamol Oral Suspension), Metaxalone 640mg Tablet, and Tanlor® (Methocarbamol 1,000mg Tablet) – See Appendix R

- A. Current Prior Authorization Criteria
- B. Utilization of Muscle Relaxant Medications
- C. Prior Authorization of Muscle Relaxant Medications
- D. Market News and Updates
- E. Product Summaries
- F. Carisoprodol Products Cost Comparison
- G. College of Pharmacy Recommendations
- H. Utilization Details of Muscle Relaxant Medications

Items to be presented by Dr. DeRemer, Dr. Haymore, Chairman:

21. 30-Day Notice to Prior Authorize Andembry® (Garadacimab-gxii), Dawnzera™ (Donidalorsen), and Ekterly® (Sebetralstat) and Create a Product Based Prior Authorization (PBPA) Category for the Hereditary Angioedema (HAE) Medications – See Appendix S

- A. Current Prior Authorization Criteria
- B. Market News and Updates
- C. Product Summaries
- D. Estimation of Savings
- E. College of Pharmacy Recommendations

Items to be presented by Dr. O'Halloran, Dr. Haymore, Chairman:

22. Annual Review of Antidepressants and 30-Day Notice to Prior Authorize Escitalopram 15mg Capsule and Raldesy™ (Trazodone Oral Solution) – See Appendix T

- A. Current Prior Authorization Criteria
- B. Utilization of Antidepressants
- C. Prior Authorization of Antidepressants
- D. Market News and Updates
- E. Cost Comparisons
- F. College of Pharmacy Recommendations
- G. Utilization Details of Antidepressants

Non-presentation items reviewed by Dr. Moss, Dr. Haymore, Chairman:

23. U.S. Food and Drug Administration (FDA) and Drug Enforcement Administration (DEA) Updates – See Appendix U

Non-presentation items reviewed by Dr. Adams, Dr. Haymore, Chairman:

24. Future Business* (Upcoming Product and Class Reviews)

No live DUR Board Meeting is scheduled for January 2026. January 2026 will be a packet-only meeting.

- A. Adiposity-Based Chronic Disease (ABCD) Medications
- B. Antihyperlipidemics
- C. Antihypertensive Medications
- D. Gastrointestinal (GI) Cancer Medications
- E. Non-Malignant Solid Tumor Medications
- F. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
- G. Ophthalmic Antibiotic Medications

*Future product and class reviews subject to change.

25. Adjournment

NOTE: An analysis of the atypical [Aged, Blind, and Disabled (ABD)] patient subgroup of the Oklahoma Medicaid population has been performed pertaining to all recommendations included in this DUR Board meeting packet to ensure fair and knowledgeable deliberation of the potential impact of the recommendations on this patient population.

NOTE: Oklahoma Medicaid transitioned from a fee-for-service (FFS) pharmacy benefit to a managed care pharmacy benefit for most members on April 1, 2024. At that time, the majority of SoonerCare members were transitioned to one of the three managed care SoonerSelect plans: Aetna, Humana, or Oklahoma Complete Health. SoonerSelect data has been provided to the College of Pharmacy and has been used in analyses throughout this DUR Board meeting packet. The data included in this DUR Board meeting packet combines FFS and managed care utilization data. The managed care utilization and prior authorization (PA) data reported in this packet is based solely on the data provided by the SoonerSelect plans. SoonerSelect PA data only includes medications billed as pharmacy claims (NDC) and does not include those billed as medical claims (HCPCS), where applicable.